Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 6Pancreatic Neoplasms 4Multiple Myeloma 4Neoplasms, Plasma Cell 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Sarcoma 1Recurrence 1Rectal Diseases 1Ovarian Neoplasms 1Neoplasms by Site 1Liver Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Colorectal Neoplasms 1Colonic Neoplasms 1Colonic Diseases 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Carboplatin 46Paclitaxel 31pembrolizumab 25Cyclophosphamide 24Nivolumab 14Bevacizumab 14Topotecan 12Gemcitabine 12liposomal doxorubicin 11Filgrastim 11Cisplatin 11fludarabine 10Peripheral Blood Stem Cell Transplantation 10olaparib 8aldesleukin 7durvalumab 6Oxaliplatin 6Ipilimumab 6Interleukin-2 6Docetaxel 6niraparib 5epacadostat 5cemiplimab 5Ifosfamide 5Fulvestrant 5rucaparib 4poly ICLC 4pazopanib 4avelumab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Ovarian Neoplasms × Ascorbic Acid × Clear all
NCT00228319 2018-06-19

Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants

University of Kansas Medical Center

Phase 1/2 Completed
27 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡